Tonix Pharmaceuticals Highlights TNX-2900 Program for Prader-Willi Syndrome at FPWR Family Conference

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, recently presented an overview of its TNX-2900 program at the Foundation for Prader-Willi Research (FPWR) Family Conference in Denver, Colorado. Dr. Herbert Harris, Executive Vice President of Translational Medicine at Tonix Pharmaceuticals, provided insights into the company’s innovative approach to treating hyperphagia, a pathological overeating condition, in children and adolescents with Prader-Willi syndrome (PWS).

The presentation highlighted preclinical data demonstrating the enhancing effects of magnesium (Mg2+) on the activation of oxytocin receptors. Tonix’s TNX-2900, a potentiated intranasal oxytocin formulation, is based on this Mg2+-enhanced technology. Oxytocin is an anorexigenic hormone that reduces appetite and signals fullness. The incorporation of magnesium in TNX-2900 aims to improve receptor binding and enhance therapeutic action, potentially offering a promising treatment option for hyperphagia in PWS.

TNX-2900 has been granted Orphan Drug designation by the FDA for the treatment of PWS, a genetic disorder characterized by severe hyperphagia and obesity. Currently, there is no approved treatment for hyperphagia in PWS. Tonix Pharmaceuticals plans to submit an investigational new drug (IND) application to the FDA in the fourth quarter of 2023, marking a significant step towards addressing this unmet medical need.

Tonix Pharmaceuticals licensed the technology to treat PWS from Inserm Transfert, the private subsidiary of Inserm, the French National Institute of Health and Medical Research. This collaboration highlights the company’s commitment to advancing research and development efforts to improve the lives of individuals with PWS.

Prader-Willi syndrome affects both males and females of all races and ethnicities and is recognized as the most common genetic cause of life-threatening childhood obesity. The condition is characterized by severe hyperphagia, leading to significant complications and mortality. Currently, there is no approved treatment for the suckling deficit in infants or the obesity and hyperphagia in older children associated with PWS.

Tonix Pharmaceuticals is dedicated to commercializing, developing, discovering, and licensing therapeutics to treat and prevent human diseases. In addition to TNX-2900, the company’s development portfolio includes various product candidates targeting central nervous system conditions, rare diseases, immunology, and infectious diseases.

With its innovative approach and commitment to addressing unmet medical needs, Tonix Pharmaceuticals is poised to make a significant impact in the field of Prader-Willi syndrome and improve the lives of individuals affected by this challenging condition.

For more information about Tonix Pharmaceuticals and its ongoing research and development efforts, please visit www.tonixpharma.com.